Fractyl Health, Inc. (NASDAQ:GUTS) Insider Jay David Caplan Sells 22,346 Shares

Fractyl Health, Inc. (NASDAQ:GUTS - Get Free Report) insider Jay David Caplan sold 22,346 shares of Fractyl Health stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $1.81, for a total value of $40,446.26. Following the transaction, the insider now directly owns 153,544 shares in the company, valued at $277,914.64. The trade was a 12.70 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Jay David Caplan also recently made the following trade(s):

• On Monday, November 11th, Jay David Caplan sold 64,197 shares of Fractyl Health stock. The shares were sold at an average price of $2.47, for a total transaction of $158,566.59.

Fractyl Health Trading Down 6.2 %

Shares of NASDAQ:GUTS traded down $0.10 during midday trading on Friday, reaching $1.51. The company's stock had a trading volume of 282,585 shares, compared to its average volume of 407,031. Fractyl Health, Inc. has a fifty-two week low of $1.51 and a fifty-two week high of $10.69. The company has a debt-to-equity ratio of 0.60, a quick ratio of 5.57 and a current ratio of 5.58. The firm has a 50 day moving average price of $2.01 and a two-hundred day moving average price of $2.46. The firm has a market capitalization of $72.63 million and a price-to-earnings ratio of -0.12.

Fractyl Health (NASDAQ:GUTS - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.02. The business had revenue of $0.01 million during the quarter. As a group, analysts forecast that Fractyl Health, Inc. will post -1.66 earnings per share for the current year.

Analyst Ratings Changes

Separately, Morgan Stanley reduced their price objective on shares of Fractyl Health from $18.00 to $10.00 and set an "overweight" rating on the stock in a research note on Monday.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of GUTS. Jane Street Group LLC bought a new stake in Fractyl Health in the third quarter valued at $25,000. Parkside Financial Bank & Trust acquired a new stake in shares of Fractyl Health in the 4th quarter valued at about $27,000. SG Americas Securities LLC acquired a new stake in shares of Fractyl Health in the 3rd quarter valued at about $33,000. Raymond James Financial Inc. bought a new stake in Fractyl Health in the 4th quarter valued at about $34,000. Finally, JPMorgan Chase & Co. raised its stake in Fractyl Health by 335.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 14,807 shares of the company's stock worth $37,000 after buying an additional 11,406 shares during the period.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.